DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
Triciribine is an investigational drug.
There have been 5 clinical trials for Triciribine. The most recent clinical trial was a Phase 1 trial, which was initiated on September 1st 2014.
The most common disease conditions in clinical trials are Leukemia, Neoplasms, and Neoplasm Metastasis. The leading clinical trial sponsors are Prescient Therapeutics, Ltd., VioQuest Pharmaceuticals, and National Cancer Institute (NCI).
There is one US patent protecting this investigational drug and eight international patents.
Recent Clinical Trials for Triciribine
|A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute Leukemia||Prescient Therapeutics, Ltd.||Phase 1/Phase 2|
|PTX-200 and Carboplatin in Ovarian Cancer||Prescient Therapeutics, Ltd.||Phase 1/Phase 2|
|Triciribine Phosphate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer||National Cancer Institute (NCI)||Phase 1/Phase 2|
Top disease conditions for Triciribine
Top clinical trial sponsors for Triciribine
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Triciribine||Start Trial||Method of diagnosing and treating cancer using B-catenin splice variants||The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC)||Start Trial|
|Triciribine||Start Trial||Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers||Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC)||Start Trial|
|Triciribine||Start Trial||Use of inhibitors of Bruton'S tyrosine kinase (Btk)||Pharmacyclics LLC (Sunnyvale, CA)||Start Trial|
|Triciribine||Start Trial||Use of inhibitors of Bruton's tyrosine kinase (Btk)||Pharmacyclics LLC (Sunnyvale, CA)||Start Trial|
|Triciribine||Start Trial||Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity||The University of North Carolina at Chapel Hill (Chapel Hill, NC)||Start Trial|
|Triciribine||Start Trial||Inhibition of hypoxia-inducible factor activity with carica papaya extracts||The Regents of the University of California (Oakland, CA) Universiti Putra Malaysia (Selangor Darul Ehsan, MY)||Start Trial|
|Triciribine||Start Trial||Compositions and methods including celecoxib and plumbagin relating to treatment of cancer||The Penn State Research Foundation (University Park, PA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Triciribine||European Patent Office||1851340||2025-02-10||Start Trial|
|Triciribine||Hong Kong||1115165||2025-02-10||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|